Today: 16 May 2026
Browse Category

LSE:SGRO 9 March 2026

UK stock market today: FTSE 100 pares early slump as oil shock hits London shares

UK stock market today: FTSE 100 pares early slump as oil shock hits London shares

FTSE 100 closed down 0.3% and FTSE 250 fell 1.6% after Brent crude surged over 25% to $119.50 a barrel amid the U.S.-Iran war. UK gilt yields jumped as traders shifted bets toward a possible Bank of England rate hike. Sterling weakened, while energy stocks like Shell and BP rose. Homebuilders and property shares led declines, with Persimmon down 5.5%.
9 March 2026
········

Stock Market Today

  • Calix (CALX) Shares Drop Amidst Mixed Valuation Signals and High P/E Risk
    May 15, 2026, 6:14 PM EDT. Calix (CALX) stock has plunged about 17% in the past month and 24% over three months, with year-to-date declines around 25%. Despite this, the company shows recent revenue and net income growth, fueling a debate on whether shares are undervalued or overpriced. The most followed analysis pegs Calix's fair value at $71.67, significantly above the last close near $40, highlighting a 43.8% undervaluation. However, the stock trades at a high price-to-earnings (P/E) ratio of 75.8, well above the US Communications industry average of 36.3, indicating potential downside if growth disappoints. Key risks include slower adoption of AI and platform upgrades and rising data privacy costs. Investors are advised to weigh fundamentals closely amid mixed sentiment and valuation complexities.

Latest articles

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

15 May 2026
Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
AXT delays annual meeting to June after AI-driven stock jump

AXT delays annual meeting to June after AI-driven stock jump

15 May 2026
AXT adjourned its 2026 annual meeting after failing to reach a quorum, rescheduling for June 4. The company seeks shareholder approval to raise authorized common shares to 120 million from 70 million. Shares closed at $123.78, up 7.65%, after a volatile session. China’s export controls on indium phosphide remain a key risk for AXT’s business.
Hyperscale Data moves higher after $5M tender, all eyes on 10-Q

Hyperscale Data moves higher after $5M tender, all eyes on 10-Q

15 May 2026
Hyperscale Data plans a tender offer to buy up to $5 million of Class A shares at $0.21 each, above the last GPUS trade at $0.146. The company reported a preliminary first-quarter net loss of about $30 million on revenue of $44 million and filed a late notice for its Form 10-Q. The offer is pending board and regulatory approval.
Go toTop